TransMedics: 3 Key Takeaways for Long-Term Investors
Its ENHANCE heart and DENOVO lung programs target thousands of procedures that currently use no machine preservation at all.
TransMedics reported robust third-quarter 2026 revenue of $203 million, a 41% year-over-year increase, despite a 6% decline in U.S. donor organ availability. CEO Waleed Hassanein highlighted two key growth initiatives: expanding enrollment in ENHANCE heart and DENOVO lung clinical programs, which could add 2,000 to 5,000 annual U.S. heart and lung cases, and developing a portable kidney system for kidneys discarded due to prolonged ischemia.
Hassanein expressed strong momentum, driven by hospital adoption and global expansion, with all-time high case volumes and operating leverage expected from next-generation organ preservation systems.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
